{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:51:11Z","timestamp":1773708671500,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T00:00:00Z","timestamp":1634860800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T00:00:00Z","timestamp":1634860800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82171970"],"award-info":[{"award-number":["82171970"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81871385"],"award-info":[{"award-number":["81871385"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81822037"],"award-info":[{"award-number":["81822037"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81972446"],"award-info":[{"award-number":["81972446"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"national institutes of health","doi-asserted-by":"publisher","award":["P30CA014520"],"award-info":[{"award-number":["P30CA014520"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"beijing science foundation for distinguished young scholars","award":["JQ19028"],"award-info":[{"award-number":["JQ19028"]}]},{"name":"pku medicine-x youth program","award":["PKU2021LCXQ023"],"award-info":[{"award-number":["PKU2021LCXQ023"]}]},{"name":"open funding project of the state key laboratory of biochemical engineering","award":["2020KF-01"],"award-info":[{"award-number":["2020KF-01"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s00259-021-05593-9","type":"journal-article","created":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T10:06:34Z","timestamp":1634897194000},"page":"1470-1481","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["64Cu-labeled daratumumab F(ab\u2032)2 fragment enables early visualization of CD38-positive lymphoma"],"prefix":"10.1007","volume":"49","author":[{"given":"Lei","family":"Kang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cuicui","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Logan","family":"Sutherlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaelyn V.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nan","family":"Huo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongkang","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan W.","family":"Engle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongfu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengzhi","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dawei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojie","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weibo","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,22]]},"reference":[{"key":"5593_CR1","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059\u201368. https:\/\/doi.org\/10.1200\/JCO.2013.54.8800.","journal-title":"J Clin Oncol"},{"key":"5593_CR2","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.3389\/fimmu.2019.01187","volume":"10","author":"KA Hogan","year":"2019","unstructured":"Hogan KA, Chini CCS, Chini EN. The multi-faceted ecto-enzyme CD38: roles in immunomodulation, cancer, aging, and metabolic diseases. Front Immunol. 2019;10:1187. https:\/\/doi.org\/10.3389\/fimmu.2019.01187.","journal-title":"Front Immunol"},{"key":"5593_CR3","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","volume":"373","author":"HM Lokhorst","year":"2015","unstructured":"Lokhorst HM, Plesner T, Laubach JP, Nahi H, Gimsing P, Hansson M, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med. 2015;373:1207\u201319. https:\/\/doi.org\/10.1056\/NEJMoa1506348.","journal-title":"N Engl J Med"},{"key":"5593_CR4","doi-asserted-by":"publisher","first-page":"4290","DOI":"10.1158\/1078-0432.CCR-16-3192","volume":"23","author":"X Feng","year":"2017","unstructured":"Feng X, Zhang L, Acharya C, An G, Wen K, Qiu L, et al. Targeting CD38 suppresses induction and function of T regulatory cells to mitigate immunosuppression in multiple myeloma. Clin Cancer Res. 2017;23:4290\u2013300. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-3192.","journal-title":"Clin Cancer Res"},{"key":"5593_CR5","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13045-016-0283-0","volume":"9","author":"L Sanchez","year":"2016","unstructured":"Sanchez L, Wang Y, Siegel DS, Wang ML. Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma. J Hematol Oncol. 2016;9:51. https:\/\/doi.org\/10.1186\/s13045-016-0283-0.","journal-title":"J Hematol Oncol"},{"key":"5593_CR6","doi-asserted-by":"publisher","unstructured":"Calabretta E, Carlo-Stella C. The many facets of CD38 in lymphoma: from tumor-microenvironment cell interactions to acquired resistance to immunotherapy. Cells. 2020;9. doi:https:\/\/doi.org\/10.3390\/cells9040802.","DOI":"10.3390\/cells9040802"},{"key":"5593_CR7","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/s41375-020-0810-4","volume":"35","author":"D Viola","year":"2021","unstructured":"Viola D, Dona A, Caserta E, Troadec E, Besi F, McDonald T, et al. Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting. Leukemia. 2021;35:189\u2013200. https:\/\/doi.org\/10.1038\/s41375-020-0810-4.","journal-title":"Leukemia"},{"key":"5593_CR8","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1053\/j.seminhematol.2018.02.009","volume":"55","author":"N Pandit-Taskar","year":"2018","unstructured":"Pandit-Taskar N. Functional imaging methods for assessment of minimal residual disease in multiple myeloma: current status and novel ImmunoPET based methods. Semin Hematol. 2018;55:22\u201332. https:\/\/doi.org\/10.1053\/j.seminhematol.2018.02.009.","journal-title":"Semin Hematol"},{"key":"5593_CR9","doi-asserted-by":"publisher","first-page":"e80","DOI":"10.1016\/s2352-3026(20)30365-3","volume":"8","author":"SF Barrington","year":"2021","unstructured":"Barrington SF, Trotman J. The role of PET in the first-line treatment of the most common subtypes of non-Hodgkin lymphoma. The Lancet Haematology. 2021;8:e80\u201393. https:\/\/doi.org\/10.1016\/s2352-3026(20)30365-3.","journal-title":"The Lancet Haematology"},{"key":"5593_CR10","first-page":"176","volume":"9","author":"A Borra","year":"2019","unstructured":"Borra A, Morbelli S, Zwarthoed C, Bianchi A, Bergesio F, Chauvie S, et al. Dual-point FDG-PET\/CT for treatment response assessment in Hodgkin lymphoma, when an FDG-avid lesion persists after treatment. Am J Nucl Med Mol Imaging. 2019;9:176\u201384.","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"5593_CR11","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3389\/fmed.2019.00069","volume":"6","author":"B Jamet","year":"2019","unstructured":"Jamet B, Bailly C, Carlier T, Touzeau C, Nanni C, Zamagni E, et al. Interest of pet imaging in multiple myeloma. Front Med. 2019;6:69. https:\/\/doi.org\/10.3389\/fmed.2019.00069.","journal-title":"Front Med"},{"key":"5593_CR12","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1021\/acs.molpharmaceut.7b01168","volume":"15","author":"L Kang","year":"2018","unstructured":"Kang L, Jiang D, Ehlerding EB, Barnhart TE, Ni D, Engle JW, et al. Noninvasive trafficking of brentuximab vedotin and PET imaging of CD30 in lung cancer murine models. Mol Pharm. 2018;15:1627\u201334. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.7b01168.","journal-title":"Mol Pharm"},{"key":"5593_CR13","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1007\/s00259-018-3941-3","volume":"45","author":"L Kang","year":"2018","unstructured":"Kang L, Jiang D, England CG, Barnhart TE, Yu B, Rosenkrans ZT, et al. ImmunoPET imaging of CD38 in murine lymphoma models using (89)Zr-labeled daratumumab. Eur J Nucl Med Mol Imaging. 2018;45:1372\u201381. https:\/\/doi.org\/10.1007\/s00259-018-3941-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5593_CR14","doi-asserted-by":"publisher","first-page":"3787","DOI":"10.1021\/acs.chemrev.9b00738","volume":"120","author":"W Wei","year":"2020","unstructured":"Wei W, Rosenkrans ZT, Liu J, Huang G, Luo QY, Cai W. ImmunoPET: concept, design, and applications. Chem Rev. 2020;120:3787\u2013851. https:\/\/doi.org\/10.1021\/acs.chemrev.9b00738.","journal-title":"Chem Rev"},{"key":"5593_CR15","doi-asserted-by":"publisher","first-page":"372","DOI":"10.2967\/jnumed.120.246595","volume":"62","author":"L Kang","year":"2021","unstructured":"Kang L, Li C, Rosenkrans ZT, Engle JW, Wang R, Jiang D, et al. Noninvasive evaluation of CD20 expression using (64)Cu-labeled F(ab\u2019)2 fragments of obinutuzumab in lymphoma. J Nucl Med. 2021;62:372\u20138. https:\/\/doi.org\/10.2967\/jnumed.120.246595.","journal-title":"J Nucl Med"},{"key":"5593_CR16","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1148\/radiol.2020192621","volume":"295","author":"GA Ulaner","year":"2020","unstructured":"Ulaner GA, Sobol NB, O\u2019Donoghue JA, Kirov AS, Riedl CC, Min R, et al. CD38-targeted immuno-PET of multiple myeloma: from xenograft models to first-in-human imaging. Radiology. 2020;295:606\u201315. https:\/\/doi.org\/10.1148\/radiol.2020192621.","journal-title":"Radiology"},{"key":"5593_CR17","first-page":"1271","volume":"44","author":"I Verel","year":"2003","unstructured":"Verel I, Visser GW, Boellaard R, Stigter-van Walsum M, Snow GB, van Dongen GA. 89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies. J Nucl Med. 2003;44:1271\u201381.","journal-title":"J Nucl Med"},{"key":"5593_CR18","doi-asserted-by":"publisher","first-page":"12806","DOI":"10.1073\/pnas.1509667112","volume":"112","author":"H Luo","year":"2015","unstructured":"Luo H, Hernandez R, Hong H, Graves SA, Yang Y, England CG, et al. Noninvasive brain cancer imaging with a bispecific antibody fragment, generated via click chemistry. Proc Natl Acad Sci USA. 2015;112:12806\u201311. https:\/\/doi.org\/10.1073\/pnas.1509667112.","journal-title":"Proc Natl Acad Sci USA"},{"key":"5593_CR19","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1021\/mp300507r","volume":"10","author":"H Hong","year":"2013","unstructured":"Hong H, Zhang Y, Orbay H, Valdovinos HF, Nayak TR, Bean J, et al. Positron emission tomography imaging of tumor angiogenesis with a (61\/64)Cu-labeled F(ab\u2019)(2) antibody fragment. Mol Pharm. 2013;10:709\u201316. https:\/\/doi.org\/10.1021\/mp300507r.","journal-title":"Mol Pharm"},{"key":"5593_CR20","doi-asserted-by":"publisher","first-page":"2001879","DOI":"10.1002\/advs.202001879","volume":"8","author":"L Kang","year":"2021","unstructured":"Kang L, Li C, Rosenkrans ZT, Huo N, Chen Z, Ehlerding EB, et al. CD38-targeted theranostics of lymphoma with (89)Zr\/(177)Lu-labeled daratumumab. Adv Sci (Weinh). 2021;8:2001879. https:\/\/doi.org\/10.1002\/advs.202001879.","journal-title":"Adv Sci (Weinh)"},{"key":"5593_CR21","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1021\/acs.bioconjchem.0c00649","volume":"32","author":"C Li","year":"2021","unstructured":"Li C, Kang L, Fan K, Ferreira CA, Becker KV, Huo N, et al. ImmunoPET of CD146 in orthotopic and metastatic breast cancer models. Bioconjug Chem. 2021;32:1306\u201314. https:\/\/doi.org\/10.1021\/acs.bioconjchem.0c00649.","journal-title":"Bioconjug Chem"},{"key":"5593_CR22","doi-asserted-by":"publisher","first-page":"216","DOI":"10.2967\/jnumed.117.196063","volume":"59","author":"A Ghai","year":"2018","unstructured":"Ghai A, Maji D, Cho N, Chanswangphuwana C, Rettig M, Shen D, et al. Preclinical development of CD38-targeted [(89)Zr]Zr-DFO-daratumumab for imaging multiple myeloma. J Nucl Med. 2018;59:216\u201322. https:\/\/doi.org\/10.2967\/jnumed.117.196063.","journal-title":"J Nucl Med"},{"key":"5593_CR23","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1007\/s11307-020-01542-4","volume":"23","author":"N Cho","year":"2021","unstructured":"Cho N, Ko S, Shokeen M. Preclinical development of near-infrared-labeled CD38-targeted daratumumab for optical imaging of CD38 in multiple myeloma. Mol Imaging Biol. 2021;23:186\u201395. https:\/\/doi.org\/10.1007\/s11307-020-01542-4.","journal-title":"Mol Imaging Biol"},{"key":"5593_CR24","doi-asserted-by":"publisher","first-page":"2400","DOI":"10.1021\/acs.molpharmaceut.7b00298","volume":"14","author":"EB Ehlerding","year":"2017","unstructured":"Ehlerding EB, England CG, Jiang D, Graves SA, Kang L, Lacognata S, et al. CD38 as a PET imaging target in lung cancer. Mol Pharm. 2017;14:2400\u20136. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.7b00298.","journal-title":"Mol Pharm"},{"key":"5593_CR25","first-page":"6007","volume":"11","author":"S Li","year":"2019","unstructured":"Li S, England CG, Ehlerding EB, Kutyreff CJ, Engle JW, Jiang D, et al. ImmunoPET imaging of CD38 expression in hepatocellular carcinoma using (64)Cu-labeled daratumumab. Am J Transl Res. 2019;11:6007\u201315.","journal-title":"Am J Transl Res"},{"key":"5593_CR26","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1158\/2159-8290.Cd-17-1033","volume":"8","author":"L Chen","year":"2018","unstructured":"Chen L, Diao L, Yang Y, Yi X, Rodriguez BL, Li Y, et al. CD38-mediated immunosuppression as a mechanism of tumor cell escape from PD-1\/PD-L1 blockade. Cancer Discov. 2018;8:1156\u201375. https:\/\/doi.org\/10.1158\/2159-8290.Cd-17-1033.","journal-title":"Cancer Discov"},{"key":"5593_CR27","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.3389\/fimmu.2019.02093","volume":"10","author":"JH Lam","year":"2019","unstructured":"Lam JH, Ng HHM, Lim CJ, Sim XN, Malavasi F, Li H, et al. Expression of CD38 on macrophages predicts improved prognosis in hepatocellular carcinoma. Front Immunol. 2019;10:2093. https:\/\/doi.org\/10.3389\/fimmu.2019.02093.","journal-title":"Front Immunol"},{"key":"5593_CR28","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s00259-016-3560-9","volume":"44","author":"CG England","year":"2017","unstructured":"England CG, Rui L, Cai W. Lymphoma: current status of clinical and preclinical imaging with radiolabeled antibodies. Eur J Nucl Med Mol Imaging. 2017;44:517\u201332. https:\/\/doi.org\/10.1007\/s00259-016-3560-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5593_CR29","doi-asserted-by":"publisher","first-page":"5194","DOI":"10.1182\/bloodadvances.2020002603","volume":"4","author":"A Krishnan","year":"2020","unstructured":"Krishnan A, Adhikarla V, Poku EK, Palmer J, Chaudhry A, Biglang-Awa VE, et al. Identifying CD38+ cells in patients with multiple myeloma: first-in-human imaging using copper-64-labeled daratumumab. Blood Adv. 2020;4:5194\u2013202. https:\/\/doi.org\/10.1182\/bloodadvances.2020002603.","journal-title":"Blood Adv"},{"key":"5593_CR30","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1182\/blood-2017-09-807263","volume":"131","author":"E Caserta","year":"2018","unstructured":"Caserta E, Chea J, Minnix M, Poku EK, Viola D, Vonderfecht S, et al. Copper 64-labeled daratumumab as a PET\/CT imaging tracer for multiple myeloma. Blood. 2018;131:741\u20135. https:\/\/doi.org\/10.1182\/blood-2017-09-807263.","journal-title":"Blood"},{"key":"5593_CR31","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1007\/s00259-021-05218-1","volume":"48","author":"C Wang","year":"2021","unstructured":"Wang C, Chen Y, Hou YN, Liu Q, Zhang D, Zhao H, et al. ImmunoPET imaging of multiple myeloma with [(68)Ga]Ga-NOTA-Nb1053. Eur J Nucl Med Mol Imaging. 2021;48:2749\u201360. https:\/\/doi.org\/10.1007\/s00259-021-05218-1.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5593_CR32","doi-asserted-by":"publisher","first-page":"14289","DOI":"10.1038\/s41598-017-14112-6","volume":"7","author":"W Fumey","year":"2017","unstructured":"Fumey W, Koenigsdorf J, Kunick V, Menzel S, Sch\u00fctze K, Unger M, et al. Nanobodies effectively modulate the enzymatic activity of CD38 and allow specific imaging of CD38(+) tumors in mouse models in vivo. Sci Rep. 2017;7:14289. https:\/\/doi.org\/10.1038\/s41598-017-14112-6.","journal-title":"Sci Rep"},{"key":"5593_CR33","doi-asserted-by":"publisher","first-page":"101148","DOI":"10.1016\/j.beha.2020.101148","volume":"33","author":"GA Ulaner","year":"2020","unstructured":"Ulaner GA, Landgren CO. Current and potential applications of positron emission tomography for multiple myeloma and plasma cell disorders. Best Pract Res Clin Haematol. 2020;33:101148. https:\/\/doi.org\/10.1016\/j.beha.2020.101148.","journal-title":"Best Pract Res Clin Haematol"},{"key":"5593_CR34","doi-asserted-by":"publisher","first-page":"795","DOI":"10.2967\/jnumed.120.251983","volume":"62","author":"M Minnix","year":"2021","unstructured":"Minnix M, Adhikarla V, Caserta E, Poku E, Rockne R, Shively JE, et al. Comparison of CD38-targeted alpha- versus beta-radionuclide therapy of disseminated multiple myeloma in an animal model. J Nucl Med. 2021;62:795\u2013801. https:\/\/doi.org\/10.2967\/jnumed.120.251983.","journal-title":"J Nucl Med"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-021-05593-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-021-05593-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-021-05593-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T11:04:40Z","timestamp":1647947080000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-021-05593-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,22]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["5593"],"URL":"https:\/\/doi.org\/10.1007\/s00259-021-05593-9","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,22]]},"assertion":[{"value":"14 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All applicable international, national, and\/or institutional guidelines for the care and use of animals were followed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Weibo Cai is the scientific advisor, stockholder, and grantee of Focus-X Therapeutics, Inc. All the other authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}